WellDoc, developer of a prescription app for managing diabetes, has raised $20m financing from investors including Merck Global Health Innovation Fund.

WellDoc, a US-based healthcare technology company which provides a platform for people with chronic diseases to self-manage their condition, has raised $20m in strategic financing from investors including Merck Global Health Innovation Fund, the corporate venture capital investment affiliate of US-based healthcare company Merck, and Windham Venture Partners.

WellDoc has previously raised $35m in debt and equity from angel investors.

Ryan Sysko, co-founder and chief executive officer of WellDoc, said: “This investment will help WellDoc launch and commercialize BlueStar, the…